{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:25:56Z","timestamp":1778736356068,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH\/NCI cancer center support grant","award":["p30CA008748"],"award-info":[{"award-number":["p30CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-023-03930-0","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T11:02:08Z","timestamp":1683284528000},"page":"2434-2442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors affecting outcomes of Yttrium-90 radioembolization in heavily pretreated patients with intrahepatic cholangiocarcinoma"],"prefix":"10.1007","volume":"48","author":[{"given":"Ken","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Erinjeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlasios S.","family":"Sotirchos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amgad M.","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etay","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos T.","family":"Sofocleous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghassan K.","family":"Abou-Alfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1815-3799","authenticated-orcid":false,"given":"Anita","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman","family":"Yarmohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"issue":"9","key":"3930_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557-88.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"2","key":"3930_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-2004-828889","volume":"24","author":"Y Shaib","year":"2004","unstructured":"Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):115-25.","journal-title":"Semin Liver Dis."},{"issue":"7","key":"3930_CR3","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00268-019-04966-4","volume":"43","author":"L Wu","year":"2019","unstructured":"Wu L, Tsilimigras DI, Paredes AZ, Mehta R, Hyer JM, Merath K, et al. Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival. World J Surg. 2019;43(7):1777-87.","journal-title":"World J Surg."},{"issue":"4","key":"3930_CR4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1245\/s10434-019-08142-9","volume":"27","author":"AC Smart","year":"2020","unstructured":"Smart AC, Goyal L, Horick N, Petkovska N, Zhu AX, Ferrone CR, et al. Hypofractionated Radiation Therapy for Unresectable\/Locally Recurrent Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27(4):1122-9.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"3930_CR5","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29824","volume":"122","author":"IT Konstantinidis","year":"2016","unstructured":"Konstantinidis IT, Groot Koerkamp B, Do RK, Gonen M, Fong Y, Allen PJ, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758-65.","journal-title":"Cancer."},{"issue":"2","key":"3930_CR6","doi-asserted-by":"publisher","first-page":"W205","DOI":"10.2214\/AJR.10.4937","volume":"196","author":"JH Kim","year":"2011","unstructured":"Kim JH, Won HJ, Shin YM, Kim KA, Kim PN. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol. 2011;196(2):W205-9.","journal-title":"AJR Am J Roentgenol."},{"issue":"3","key":"3930_CR7","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1016\/j.ejrad.2010.09.019","volume":"80","author":"JH Kim","year":"2011","unstructured":"Kim JH, Won HJ, Shin YM, Kim PN, Lee SG, Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol. 2011;80(3):e221-5.","journal-title":"Eur J Radiol."},{"issue":"12","key":"3930_CR8","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1245\/s10434-013-3127-y","volume":"20","author":"O Hyder","year":"2013","unstructured":"Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20(12):3779-86.","journal-title":"Ann Surg Oncol."},{"key":"3930_CR9","doi-asserted-by":"publisher","first-page":"1112500","DOI":"10.3389\/fbioe.2022.1112500","volume":"10","author":"J Wang","year":"2022","unstructured":"Wang J, Xue Y, Liu R, Wen Z, Ma Z, Yang X, et al. DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study. Front Bioeng Biotechnol. 2022;10:1112500.","journal-title":"Front Bioeng Biotechnol."},{"issue":"6","key":"3930_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jvir.2022.02.016","volume":"33","author":"DA Schartz","year":"2022","unstructured":"Schartz DA, Porter M, Schartz E, Kallas J, Gupta A, Butani D, et al. Transarterial Yttrium-90 Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. 2022;33(6):679-86.","journal-title":"J Vasc Interv Radiol."},{"issue":"1","key":"3930_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020;6(1):51-9.","journal-title":"JAMA Oncol."},{"key":"3930_CR12","doi-asserted-by":"crossref","unstructured":"Ahmed O, Yu Q, Patel M, Hwang G, Pillai A, Liao CY, et al. Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as First Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2022.","DOI":"10.1016\/j.jvir.2022.03.384"},{"issue":"8","key":"3930_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00270-022-03183-2","volume":"45","author":"AN Gupta","year":"2022","unstructured":"Gupta AN, Gordon AC, Gabr A, Kalyan A, Kircher SM, Mahalingam D, et al. Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort. Cardiovasc Intervent Radiol. 2022;45(8):1117-28.","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"8","key":"3930_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jvir.2019.03.018","volume":"30","author":"J White","year":"2019","unstructured":"White J, Carolan-Rees G, Dale M, Patrick HE, See TC, Bell JK, et al. Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study. J Vasc Interv Radiol. 2019;30(8):1185-92.","journal-title":"Observational Study. J Vasc Interv Radiol."},{"issue":"3","key":"3930_CR15","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.31829","volume":"74","author":"T Boerner","year":"2021","unstructured":"Boerner T, Drill E, Pak LM, Nguyen B, Sigel CS, Doussot A, et al. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology. 2021;74(3):1429-44.","journal-title":"Hepatology."},{"key":"3930_CR16","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/ncomms6696","volume":"5","author":"S Zou","year":"2014","unstructured":"Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5:5696.","journal-title":"Nat Commun."},{"issue":"4","key":"3930_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00270-007-9064-z","volume":"30","author":"RJ Lewandowski","year":"2007","unstructured":"Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Jr., Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30(4):571-92.","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"10","key":"3930_CR18","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1097\/01.RVI.0000236744.34720.73","volume":"17","author":"R Salem","year":"2006","unstructured":"Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17(10):1571-93.","journal-title":"J Vasc Interv Radiol."},{"issue":"8","key":"3930_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","volume":"46","author":"R Salem","year":"2019","unstructured":"Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695-704.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"3930_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015;17(3):251-64.","journal-title":"J Mol Diagn."},{"key":"3930_CR21","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"3930_CR22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017 [Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"20","key":"3930_CR23","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.18632\/oncotarget.28060","volume":"12","author":"R Paz-Fumagalli","year":"2021","unstructured":"Paz-Fumagalli R, Core J, Padula C, Montazeri S, McKinney J, Frey G, et al. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget. 2021;12(20):2075-88.","journal-title":"Oncotarget."},{"issue":"1","key":"3930_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","volume":"44","author":"T Helmberger","year":"2021","unstructured":"Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, et al. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21-35.","journal-title":"Cardiovasc Intervent Radiol."},{"key":"3930_CR25","doi-asserted-by":"crossref","unstructured":"Kohler M, Harders F, Lohofer F, Paprottka PM, Schaarschmidt BM, Theysohn J, et al. Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization. J Clin Med. 2019;9(1).","DOI":"10.3390\/jcm9010056"},{"key":"3930_CR26","doi-asserted-by":"crossref","unstructured":"Buettner S, Braat A, Margonis GA, Brown DB, Taylor KB, Borgmann AJ, et al. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. J Vasc Interv Radiol. 2020;31(7):1035-43 e2.","DOI":"10.1016\/j.jvir.2020.02.008"},{"issue":"9","key":"3930_CR27","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","volume":"43","author":"I Bargellini","year":"2020","unstructured":"Bargellini I, Mosconi C, Pizzi G, Lorenzoni G, Vivaldi C, Cappelli A, et al. Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study. Cardiovasc Intervent Radiol. 2020;43(9):1305-14.","journal-title":"Cardiovasc Intervent Radiol."},{"key":"3930_CR28","doi-asserted-by":"crossref","unstructured":"Robinson TJ, Du L, Matsuoka L, Sze DY, Kennedy AS, Gandhi RT, et al. Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry. J Vasc Interv Radiol. 2022.","DOI":"10.1016\/j.jvir.2022.10.042"},{"issue":"10","key":"3930_CR29","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1245\/s10434-020-08486-7","volume":"27","author":"D Riby","year":"2020","unstructured":"Riby D, Mazzotta AD, Bergeat D, Verdure L, Sulpice L, Bourien H, et al. Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27(10):3729-37.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"3930_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/bjc.2016.191","volume":"115","author":"C Mosconi","year":"2016","unstructured":"Mosconi C, Gramenzi A, Ascanio S, Cappelli A, Renzulli M, Pettinato C, et al. Yttrium-90 radioembolization for unresectable\/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer. 2016;115(3):297-302.","journal-title":"Br J Cancer."},{"issue":"13","key":"3930_CR31","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1245\/s10434-016-5454-2","volume":"23","author":"HM Park","year":"2016","unstructured":"Park HM, Yun SP, Lee EC, Lee SD, Han SS, Kim SH, et al. Outcomes for Patients with Recurrent Intrahepatic Cholangiocarcinoma After Surgery. Ann Surg Oncol. 2016;23(13):4392-400.","journal-title":"Ann Surg Oncol."}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-023-03930-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-023-03930-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-023-03930-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T02:05:39Z","timestamp":1685412339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-023-03930-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["3930"],"URL":"https:\/\/doi.org\/10.1007\/s00261-023-03930-0","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have disclosed any conflicts of interest in relation to the research being presented.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}